Overview
The main purpose of this trial is to observe whether Xingnaojing, intravenously administered within 24 hours of symptom onset on pre-hospital emergency ambulance, improves the Early neurological deterioration of acute stroke at 3 days.
Description
The TRACE is a multicenter, registry observational study. Xingnaojing injection is the only essential traditional chinese medicine on emergency ambulance used for acute stroke.The primary hypothesis of this trial is that Xingnaojing used for acute stroke within 24 hours of symptom onset on ambulance will improve the Early neurological deterioration of acute stroke at 3 days. All suspected acute stroke participants will be registered once they are taken on the ambulance. The primary outcome will be determined at 3 days.Besides, there will be a quantitative interview with emergency doctors about their knowledge and attitude on Xingnaojing for acute stroke patients.
Eligibility
Inclusion Criteria:
- Diagnosis of suspected acute stroke
- Symptom onset within 24 hours
- Age 18 .
Exclusion Criteria:
- Other conditions that lead to motor dysfunction (e.g., severe osteoarthrosis, rheumatoid arthritis);
- Other conditions that render outcomes or follow-up unlikely to be assessed; Known to be pregnant or breastfeeding;
- Non-acute stroke (result from Computed Tomography(CT) or Magnetic Resonance Imaging(MRI)).